BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

(2019) Junko Murai et al.   PHARMACOLOGY & THERAPEUTICS

Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer

(2019) Edoardo Isnaldi et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting Topoisomerase I in the Era of Precision Medicine

(2019) Anish Thomas et al.   CLINICAL CANCER RESEARCH

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination–Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

(2019) Laetitia Marzi et al.   CLINICAL CANCER RESEARCH

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers

(2018) Elisabetta Marangoni et al.   CLINICAL CANCER RESEARCH

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors

(2018) Sai-Wen Tang et al.   CLINICAL CANCER RESEARCH

Biomarkers for Homologous Recombination Deficiency in Cancer

(2018) Michal M Hoppe et al.   JNCI-Journal of the National Cancer Institute

Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors

(2018) Laetitia Marzi et al.   MOLECULAR CANCER THERAPEUTICS

SLFN11 Blocks Stressed Replication Forks Independently of ATR

(2018) Junko Murai et al.   MOLECULAR CELL

Biomarkers for Homologous Recombination Deficiency in Cancer

(2018) Michal M Hoppe et al.   JNCI-Journal of the National Cancer Institute

Expression of MT4-MMP, EGFR and RB in triple negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy

(2018) Pierre Foidart et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer

(2017) Robert W Mutter et al.   JOURNAL OF PATHOLOGY

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

(2016) Shivaani Kummar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability

(2016) Yves Pommier et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

(2015) M. H. Kang et al.   CLINICAL CANCER RESEARCH

SLFN11 inhibits checkpoint maintenance and homologous recombination repair

(2015) Y. Mu et al.   EMBO REPORTS

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer

(2015) Julie L. Boerner et al.   PLoS One

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

(2014) Agnieszka K Witkiewicz et al.   BREAST CANCER RESEARCH

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer

(2013) Iben Kümler et al.   BREAST CANCER RESEARCH AND TREATMENT

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

(2012) G. Zoppoli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents

(2011) Kristy R. Stengel et al.   CELL CYCLE

RB-pathway disruption in breast cancer

(2010) Adam Ertel et al.   CELL CYCLE

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays

(2009) Tatiana Popova et al.   GENOME BIOLOGY